Validation of an Arrhythmogenic Right Ventricular Cardiomyopathy Risk-Prediction Model in a Chinese Cohort

Nixiao Zhang1,2, Chuangshi Wang3, Alessio Gasperetti4

  • 1Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Insights

A new risk model accurately predicts ventricular arrhythmias in Asian arrhythmogenic right ventricular cardiomyopathy patients for primary prevention. Recalibration improved its performance for secondary prevention cases.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Technology

Background:

  • Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart condition.
  • Ventricular arrhythmias (VAs) are a major complication of ARVC.
  • Existing risk prediction models like ITFC and HRS criteria have limitations.

Purpose of the Study:

  • To externally validate a novel VA risk-prediction model in a Chinese ARVC population.
  • To assess the model's effectiveness in predicting ventricular events compared to previous criteria.
  • To evaluate the model's performance in both primary and secondary prevention cohorts.

Main Methods:

  • Enrolled 88 ARVC patients who received implantable cardioverter-defibrillators (ICDs) between 2005 and 2020.
  • Calculated a priori predicted VA risk using the novel model.
  • Compared predicted risk with observed rates of appropriate ICD therapies over a median follow-up of 3.9 years.

Main Results:

  • The novel model showed good predictive accuracy (C-statistic 0.833) in primary prevention patients.
  • In secondary prevention patients, the model initially underestimated risk (C-statistic 0.640).
  • Recalibration significantly improved the model's performance in secondary prevention patients (mean predicted-observed risk -0.04).

Conclusions:

  • The novel risk-prediction model is suitable for predicting arrhythmic risk in Asian ARVC patients undergoing primary prevention.
  • The model requires recalibration for accurate risk prediction in secondary prevention ARVC patients.
  • This validation supports the model's utility in diverse ARVC populations.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
75
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
57
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
93